<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00694005</url>
  </required_header>
  <id_info>
    <org_study_id>2008-0185</org_study_id>
    <nct_id>NCT00694005</nct_id>
  </id_info>
  <brief_title>Choice Of Optimal Strategy For Bifurcation Lesions With Normal Side Branch</brief_title>
  <acronym>CROSS</acronym>
  <official_title>Phase IV Study of the Choice of Optimal Strategy for Bifurcation Lesions With Normal Side Branch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few data are available about the late patency of side branches in association with the
      currently used stent types and implantation techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Among the bifurcation type, bifurcation lesion without significant side branch stenosis
      (&lt;50%) usually did not require side branch stenting, but owing to several putative mechanism
      including dissection, thrombosis formation, embolization of plaque debris, ostial compromise
      by displaced stent strut, and snow plow effect, the side branch might be compromised. In this
      situation, the strategy to achieve optimal results has not been reported. Recently, FFR study
      showed that most jailed side branch (vessel size &gt;2.0 mm. DS&gt;50%) after main branch stenting
      did not have functional significance. We compared strategies with or without routine kissing
      balloon dilatation for less than 50% stenosis after simple DES crossing for bifurcation
      lesions (bifurcation type 1.1.0, 1.0.0, and 0.1.0 according to Medina classification) with
      serial change of FFR measurement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diameter stenosis at 8-month follow-up between the kissing balloon inflation and leave alone strategy</measure>
    <time_frame>8 months</time_frame>
    <description>8 month after PCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side branch jail after main vessel stenting according to the stent type used</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (24 hours after the index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic reocclusion rate of side branch</measure>
    <time_frame>8 months</time_frame>
    <description>8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic restenosis rate of side branch and the main vessel</measure>
    <time_frame>8 months</time_frame>
    <description>8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late loss of side branch and the main vessel between angiography- and FFR-guided side branch procedure</measure>
    <time_frame>8 months</time_frame>
    <description>8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic reocclusion, restenosis rate and late loss of the side branch according to the DES type</measure>
    <time_frame>8 months</time_frame>
    <description>8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic reocclusion, restenosis rate and late loss of the side branch according to bifurcation angle and bifurcation type</measure>
    <time_frame>8 months</time_frame>
    <description>8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of major cardiac adverse events (MACE) including death, MI, stent thrombosis and target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FFR of the side branch at post-procedure and at follow-up</measure>
    <time_frame>Day 1, 8 months</time_frame>
    <description>Day 1 (immediately after the index procedure)and 8month after PCI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of peri-procedural cardiac enzyme elevation</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (24 hours after the index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluoroscopic time</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (immediately after the index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (immediately after the index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of contrast agent</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (immediately after the index procedure)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of used stents</measure>
    <time_frame>Day 1</time_frame>
    <description>Day 1 (immediately after the index procedure)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">504</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>bifurcation stent techniqe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cross over stenting without kissing balloon angioplasty &quot;leave alone&quot;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bifurcation stent technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>kissing balloon angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>kissing balloon</intervention_name>
    <description>simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions</description>
    <arm_group_label>bifurcation stent technique</arm_group_label>
    <other_name>Sirolimus, Paclitaxel, Zotarolimus and Everolimus stents</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>without kissing balloon angioplasty &quot;leave alone&quot;</intervention_name>
    <description>simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions</description>
    <arm_group_label>bifurcation stent techniqe</arm_group_label>
    <other_name>sirolimus, zotarolimus, paclitaxel, and everolimus stents</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical

               -  Patients with angina and documented ischemia or patients with documented silent
                  ischemia

               -  Patients who are eligible for intracoronary stenting

               -  Age &gt;18 years, &lt;75 ages

          -  Angiographic

               -  De novo lesion located in a major bifurcation point with the MEDINA
                  classification type 1.1.0, 1.0.0, or 0.1.0

               -  Main vessel : &gt;= 2.5 mm in vessel size, &gt;= 50% in diameter stenosis and =&lt; 50 mm
                  in lesion length by visual estimation, in which the lesion is covered with =&lt; 2
                  stents

               -  Side branch :&gt;= 2.0 mm in vessel size and &lt; 50% diameter stenosis by visual
                  estimation

        Exclusion Criteria:

          -  History of bleeding diathesis or coagulopathy

          -  Pregnant

          -  Known hypersensitivity or contra-indication to contrast agent, heparin, sirolimus,
             paclitaxel and zotarolimus

          -  Limited life-expectancy (less than 1 year) due to combined serious disease

          -  ST-elevation acute myocardial infarction =&lt; 2 weeks

          -  Characteristics of lesion:

               -  Left main disease

               -  In-stent restenosis

               -  Graft vessels

               -  TIMI flow =&lt; grade 2 in the side branch

               -  Chronic total occlusion

          -  Renal dysfunction, creatinine &gt;= 2.0mg/dL

          -  Contraindication to aspirin, clopidogrel or cilostazol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Busan Saint Mary's Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheongju Saint Mary's Hospital</name>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungsang University Hospital</name>
      <address>
        <city>Jinju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>PyeongChon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catholic University, Kangnam St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aju University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangwon University Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine</investigator_title>
  </responsible_party>
  <keyword>stent</keyword>
  <keyword>bifurcation</keyword>
  <keyword>balloon angioplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

